KZIA vs. SONN, PXMD, FWBI, SNPX, IBIO, HOTH, ALZN, KTRA, PTIX, and YMTX
Should you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Sonnet BioTherapeutics (SONN), PaxMedica (PXMD), First Wave BioPharma (FWBI), Synaptogenix (SNPX), iBio (IBIO), Hoth Therapeutics (HOTH), Alzamend Neuro (ALZN), Kintara Therapeutics (KTRA), Protagenic Therapeutics (PTIX), and Yumanity Therapeutics (YMTX). These companies are all part of the "pharmaceutical preparations" industry.
Kazia Therapeutics (NASDAQ:KZIA) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking.
In the previous week, Kazia Therapeutics and Kazia Therapeutics both had 1 articles in the media. Sonnet BioTherapeutics' average media sentiment score of 0.22 beat Kazia Therapeutics' score of -0.37 indicating that Sonnet BioTherapeutics is being referred to more favorably in the news media.
Kazia Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.
Kazia Therapeutics has a net margin of 0.00% compared to Sonnet BioTherapeutics' net margin of -11,187.19%. Kazia Therapeutics' return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.
Kazia Therapeutics received 61 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 80.95% of users gave Sonnet BioTherapeutics an outperform vote while only 52.35% of users gave Kazia Therapeutics an outperform vote.
30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sonnet BioTherapeutics has a consensus target price of $30.00, suggesting a potential upside of ∞. Given Sonnet BioTherapeutics' higher possible upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than Kazia Therapeutics.
Kazia Therapeutics has higher earnings, but lower revenue than Sonnet BioTherapeutics.
Summary
Kazia Therapeutics beats Sonnet BioTherapeutics on 7 of the 13 factors compared between the two stocks.
Get Kazia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kazia Therapeutics Competitors List
Related Companies and Tools
